Evaxion unveils proprietary genetic adjuvant technology to boost the effect of dna and mrna vaccines

Copenhagen, denmark, may 25, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the discovery and development of ai-powered immunotherapies, today unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of dna and mrna vaccines for infectious diseases and cancer.
EVAX Ratings Summary
EVAX Quant Ranking